Tom Miller Discusses How to Turn Your Research Into Your Own Company

November 28, 2023

Going from one field to the next can be a tricky thing to navigate. In this episode of Trends from the Trenches, host Stan Gloss speaks with Tom Miller, Co-Founder and CEO of Iambic Therapeutics, about his journey from academia as a professor at the California Institute of Technology to getting B-Round funding as the CEO of his own start-up. Miller discusses why he started his company, what inspired him to turn his research into an entrepreneurial venture, and how combining physics and data can create more data-efficient AI algorithms that vastly improve accuracy in prediction models. Miller also shares advice and insights for academic researchers on taking their discoveries and bringing them to the market.

Tom Miller, Co-Founder and CEO, Iambic Therapeutics
Tom Miller is a scientist and entrepreneur with a focus on the nexus of AI, chemistry, and biology. He joined the Caltech faculty in 2008 and was promoted to full professor in 2013. He's published more than 130 peer-reviewed articles and patents and received numerous awards for research excellence. In 2020, Tom co-founded and became CEO of Iambic Therapeutics, a technology-driven biopharma that is disrupting the therapeutics landscape with its generative AI drug discovery platform. Iambic has assembled a world-class team that unites pioneering AI experts and seasoned drug hunters with strong track records of success in delivering clinically validated breakthrough treatments. The Iambic platform has been demonstrated to deliver high quality, differentiated drugs to clinic with unprecedented speed and across multiple target classes and mechanisms of action. Iambic is advancing an internal pipeline of clinical assets to address unmet patient need across therapeutics areas.

Host Bio

Stan Gloss

As co-founder and Evangelist of BioTeam, Stan Gloss has been working to tell the stories of the intersection of science, data and technology since 2002. Gloss joined with fellow founding partners Bill Van Etten and Chris Dagdigian to form BioTeam in 2002 following his tenure in business development with AVAKI Corporation, a pioneer in global grid software solutions, and Blackstone Computing, a computing and IT consulting company for scientists, Gloss led the sales initiative that launched the company in the life sciences market. Gloss earned his MS at the University of Buffalo and was a department chairman and faculty member at Quinnipiac University.

A life science IT consulting firm at the intersection of science, data, and technology, BioTeam builds innovative scientific data ecosystems that close the gap between what scientists want to do with data—and what they can do. Learn more at www.bioteam.net.